IVIG To SCIG Transition denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ivig to scig transition are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies the IVIG-to-SCIG Transition as Duplicate Therapy

Blue Cross Blue Shield sometimes denies a request to transition from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG) on the grounds that both are immunoglobulin replacement and therefore constitute duplicate therapy. This logic misreads what a transition request actually is: you are not asking to receive both forms simultaneously. You are asking to change the route of administration while maintaining the same underlying therapy. Appeals on this ground succeed regularly because the clinical record can document the switch, not an addition.

## Why This Denial Is Appealable

A duplicate-therapy denial is a coverage determination, not a clinical judgment, and you have a federally protected right to challenge it. Under ACA §2719, most non-grandfathered plans must offer internal appeal followed by independent external review. Under ERISA §503, employer-sponsored plans must provide a full-and-fair review process. You typically have up to 180 days from the denial notice to file an internal appeal, and external review requests generally must be submitted within 4 months of exhausting internal appeals — confirm exact deadlines from your Explanation of Benefits (EOB).

If continuing the current IVIG while the transition is being denied would cause serious harm, request an expedited appeal (decision often within 72 hours).

## The Concrete Appeal Process

1. Request the full denial letter and the specific BCBS coverage policy cited. 2. File a written internal appeal clearly stating that SCIG is a transition of route, not a second drug added alongside IVIG. 3. If the internal appeal is denied, file for independent external review with your state's insurance department or the federal exchange reviewer. 4. Keep dated copies of every submission and track all response deadlines.

## Documentation to Gather

• Diagnosis confirmation: Chart notes establishing the immunodeficiency or other condition requiring immunoglobulin replacement therapy, including relevant specialist letters.
• Prior-treatment history: Full IVIG infusion history — dates, settings, and documented outcomes or tolerability issues.
• Clinical rationale for transition: Prescriber letter explaining why SCIG is the clinically appropriate next step (e.g., tolerability, venous access, patient independence, quality of life) and confirming that IVIG will be discontinued upon SCIG initiation.
• Transition plan: Written protocol showing the overlap period (if any) is a structured, time-limited transition, not concurrent duplicate therapy.

## Criteria-Mapping Structure

Pull the exact language from BCBS's published medical/coverage policy for immunoglobulin therapy and from the FDA-approved prescribing information for the specific SCIG product your prescriber has ordered. For each requirement in those documents, insert the matching chart fact:

| Policy/Label Requirement | Your Chart Evidence | |---|---| | [Copy exact criterion from BCBS policy] | [Insert chart fact — date, note, result] | | [Copy exact criterion from BCBS policy] | [Insert chart fact] |

This side-by-side format makes it immediately clear to the reviewer that the request is a substitution, not an addition, and that every criterion is met.